- Findings from the RELIEF study in France showed for the first time, in the largest retrospective analysis of its kind of nearly 75,000 people living with diabetes, use of the FreeStyle Libre system ...

Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) ...

The study was carried out at 24 clinical sites across the UK and included 303 participants.

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...

Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce a new data integration with continuous glucose monitoring (CGM ...

At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency's strongest, ...

Add Yahoo as a preferred source to see more of our stories on Google. A subset of FreeStyle Libre 3 plus sensors may provide incorrect low glucose reading, Health Canada says. (Brian Morris/CBC - ...

FreeDM2 randomized controlled trial shows Libre technology helps people with type 2 diabetes on basal insulin improve glucose management: Abbott Park, Illinois Saturday, March 14, ...